Loading...
Header Logo
Keywords
Last Name
Institution

David A Smelson PsyD

TitleProfessor
InstitutionUniversity of Massachusetts Medical School
DepartmentPsychiatry
AddressUniversity of Massachusetts Medical School
365 Plantation Street, Biotech One
Worcester MA 01605
Phone508-856-3768
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentPsychiatry

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentMillennium MD/PhD Program


    Collapse Biography 
    Collapse education and training
    Illinois School of Professional Psychology at Argosy University, Chicago, IL, United StatesBSProfessional Studies
    Upsala College, East Orange, NJ, United StatesMSPsychology
    Illinois School of Professional Psychology at Argosy University, Chicago, IL, United StatesPSYDPsychology

    Collapse Overview 
    Collapse overview

    Dr. David Smelson is a Tenured Professor of Psychiatry at the University of Massachusetts Medical School, and former Vice Chair of Clinical Research, a position he held from 2008-2018. He currently directs the University of Massachusetts Medical School, Center of Excellence in Addictions. He has been consecutively funded federally for the past 25 years by NIH (NIDA, NIAAA, NCCIH), VA, BJA and SAMHSA. His work focuses on studying and implementing treatments for addiction and co-occurring mental health and substance use.

    Examples of funding include

    NIH/NIDA R41DA044030-01A1 David Smelson (PI) 
    Title: MISSION-U: A Multimedia Training Tool for Treating Individuals with Co-occurring Mental Health and Substance Use Disorders
    This study involves the partnering with a small business to commercialize continuing education for the MISSION Model and creating a continuing education platform for MISSION.
    Costs: $243,000, direct & indirect costs
    Role: Principal Investigator (

    NIH/NIDA R42 AA026751-2 David Smelson (PI) 
    Title: MISSION-U: A Multimedia Training Tool for Treating Individuals with Co-occurring Mental Health and Substance Use Disorders
    This is a phase 2 study in partnership between UMASS Medical School and Praxis to commercialize a continuing education e-learning program to train treatment providers on the MISSION Model.
    Costs: $1,499,913.00, direct & indirect costs
    Role: Principal Investigator

    NIDA K23 Award Stephanie Carreiro (PI) 
    Title: iTransform: Wearable Biosensors to Detect the Evolution of Opioid Tolerance in Opioid Naïve Individuals
    This project utilizes machine learning approaches to evaluate opioid use and the evolution of tolerance in opioid naive individuals as measured by a wearable biosensor.
    Costs: $800,000.00, direct & indirect costs
    Role: Mentor (donated)

    SAMHSA CSAT 1H79TI080430 David Smelson (PI) 
    Title: Maintaining Independence and Sobriety through Systems Integration, Outreach and Networking-Western Massachusetts (MISSION-West)
    The goals of this project are to implement and evaluate the MISSION model for ending chronic homelessness in Springfield Metro Area.
    Costs: $2,135,454.00, direct & indirect costs
    Role: Principal Investigator

    BRIDGE QUERI Center of Excellence
    Title: The BRIDGE QUERI
    The BRIDGE QUERI includes a series of center cores and four projects that focuses on interventions for vulnerable populations of Veterans, including those experiencing homelessness, those with HIV and Hepatitis C and those exiting incarceration. The primary contribution of these projects and the center cores will be to refine service delivery models to address the health care and other service needs of these underrepresented populations.
    Costs: $3,975,000.00, direct & indirect costs.
    Role: Co-Principal Investigator 

     VA HSR&D Investigator Initiated Research Daniel Blonigen, David Smelson (Co-PIs) 
    Title: Improving Treatment Engagement and Outcomes among Justice-involved Veterans
    This project will be a multisite RCT to test the effectiveness of Moral Reconation Therapy to reduce risk for criminal recidivism and improve health-related outcomes among justice-involved Veterans.
    Costs: $1,362,265.00, direct costs




    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Byrne T, Baggett T, Land T, Bernson D, Hood ME, Kennedy-Perez C, Monterrey R, Smelson D, Dones M, Bharel M. A classification model of homelessness using integrated administrative data: Implications for targeting interventions to improve the housing status, health and well-being of a highly vulnerable population. PLoS One. 2020; 15(8):e0237905. PMID: 32817717.
      View in: PubMed
    2. Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, Binswanger IA. Disparities in Access to Medications for Opioid Use Disorder in the Veterans Health Administration. J Addict Med. 2020 Aug 18. PMID: 32826617.
      View in: PubMed
    3. Finlay AK, Morse E, Stimmel M, Taylor E, Timko C, Harris AHS, Smelson D, Yu M, Blue-Howells J, Binswanger IA. Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study. J Gen Intern Med. 2020 Jun 24. PMID: 32583337.
      View in: PubMed
    4. Carreiro S, Chintha KK, Shrestha S, Chapman B, Smelson D, Indic P. Wearable sensor-based detection of stress and craving in patients during treatment for substance use disorder: A mixed methods pilot study. Drug Alcohol Depend. 2020 Mar 03; 209:107929. PMID: 32193048.
      View in: PubMed
    5. Blonigen DM, Macia KS, Smelson D, Timko C. Criminal recidivism among justice-involved veterans following substance use disorder residential treatment. Addict Behav. 2020 Feb 15; 106:106357. PMID: 32120199.
      View in: PubMed
    6. Boyer EW, Levy S, Smelson D, Vargas S, Casey A. The Clinical Assessment of Vaping Exposure. J Addict Med. 2020 Feb 06. PMID: 32032211.
      View in: PubMed
    7. Smelson DA, Gaba A, Pressman K, Clary KM, Shaffer PM, Pinals DA. Embedding a Co-occurring Disorders Rehabilitation Intervention in Veterans Courts: A Pilot Study with Male Veterans. Community Ment Health J. 2020 Jan 31. PMID: 32006293.
      View in: PubMed
    8. Ellison ML, Schutt RK, Yuan LH, Mitchell-Miland C, Glickman ME, McCarthy S, Smelson D, Schultz MR, Chinman M. Impact of Peer Specialist Services on Residential Stability and Behavioral Health Status Among Formerly Homeless Veterans With Cooccurring Mental Health and Substance Use Conditions. Med Care. 2020 Jan 07. PMID: 31914105.
      View in: PubMed
    9. Midboe AM, Byrne T, Smelson D, Jasuja G, McInnes K, Troszak LK. The Opioid Epidemic In Veterans Who Were Homeless Or Unstably Housed. Health Aff (Millwood). 2019 Aug; 38(8):1289-1297. PMID: 31381401.
      View in: PubMed
    10. Pinals DA, Gaba A, Clary KM, Barber J, Reiss J, Smelson D. Implementation of MISSION-Criminal Justice in a Treatment Court: Preliminary Outcomes Among Individuals With Co-occurring Disorders. Psychiatr Serv. 2019 Jul 24; appips201800570. PMID: 31337322.
      View in: PubMed
    11. Corrigan PW, Qin S, Davidson L, Schomerus G, Shuman V, Smelson D. Public Perceptions of Recovery Prospects and Peer Style (Support and Confrontation) in Services for Serious Mental Illness Versus Substance Use Disorder. J Dual Diagn. 2019 Jul 16; 1-7. PMID: 31311451.
      View in: PubMed
    12. Corrigan PW, Qin S, Davidson L, Schomerus G, Shuman V, Smelson D. How does the public understand recovery from severe mental illness versus substance use disorder? Psychiatr Rehabil J. 2019 Jun 27. PMID: 31246074.
      View in: PubMed
    13. Holzhauer CG, Byrne T, Simmons MM, Smelson D, Epstein EE. Profiles of Clinical Need Among Homeless Individuals with Dual Diagnoses. Community Ment Health J. 2019 Jun 24. PMID: 31236735.
      View in: PubMed
    14. Hanna J, Kubiak S, Pasman E, Gaba A, Andre M, Smelson D, Pinals DA. Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: Application of the consolidated framework for implementation research in a cross-system initiative. J Subst Abuse Treat. 2019 Jun 20. PMID: 31285078.
      View in: PubMed
    15. Corrigan PW, Larson JE, Smelson D, Andra M. Recovery, peer support and confrontation in services for people with mental illness and/or substance use disorder. Br J Psychiatry. 2019 Mar; 214(3):130-132. PMID: 30774058.
      View in: PubMed
    16. Smelson DA, Perez CK, Farquhar I, Byrne T, Colegrove A. Permanent Supportive Housing and Specialized Co-Occurring Disorders Wraparound Services for Homeless Individuals. J Dual Diagn. 2019 Jan 04; 1-10. PMID: 30609903.
      View in: PubMed
    17. Jasuja GK, Ameli O, Miller DR, Land T, Bernson D, Rose AJ, Berlowitz DR, Smelson DA. Overdose risk for veterans receiving opioids from multiple sources. Am J Manag Care. 2018 Nov; 24(11):536-540. PMID: 30452210.
      View in: PubMed
    18. Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, Bowe T, Harris AHS. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 Dec; 95:43-47. PMID: 30352669.
      View in: PubMed
    19. Smelson DA, Chinman M, Hannah G, Byrne T, McCarthy S. An evidence-based co-occurring disorder intervention in VA homeless programs: outcomes from a hybrid III trial. BMC Health Serv Res. 2018 May 05; 18(1):332. PMID: 29728148.
      View in: PubMed
    20. McIlvane WJ, Kledaras JB, Gerard CJ, Wilde L, Smelson D. Algorithmic analysis of relational learning processes in instructional technology: Some implications for basic, translational, and applied research. Behav Processes. 2018 Jul; 152:18-25. PMID: 29544867.
      View in: PubMed
    21. Blonigen DM, Cucciare MA, Timko C, Smith JS, Harnish A, Kemp L, Rosenthal J, Smelson D. Study protocol: a hybrid effectiveness-implementation trial of Moral Reconation Therapy in the US Veterans Health Administration. BMC Health Serv Res. 2018 03 07; 18(1):164. PMID: 29514649.
      View in: PubMed
    22. Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA, Samek B, Duffy MK, Sawh L. Integrating a Co-occurring Disorders Intervention in Drug Courts: An Open Pilot Trial. Community Ment Health J. 2018 Mar 07. PMID: 29516336.
      View in: PubMed
    23. Carreiro S, Chai PR, Carey J, Lai J, Smelson D, Boyer EW. mHealth for the Detection and Intervention in Adolescent and Young Adult Substance Use Disorder. Curr Addict Rep. 2018 Jun; 5(2):110-119. PMID: 30148037.
      View in: PubMed
    24. DiGirolamo GJ, Gonzalez G, Smelson D, Guevremont N, Andre MI, Patnaik PO, Zaniewski ZR. Increased Depression and Anxiety Symptoms are Associated with More Breakdowns in Cognitive Control to Cocaine Cues in Veterans with Cocaine Use Disorder. J Dual Diagn. 2017 Oct-Dec; 13(4):298-304. PMID: 29120266.
      View in: PubMed
    25. Simmons MM, Fincke BG, Drainoni ML, Kim B, Byrne T, Smelson D, Casey K, Ellison ML, Visher C, Blue-Howells J, McInnes DK. A two-state comparative implementation of peer-support intervention to link veterans to health-related services after incarceration: a study protocol. BMC Health Serv Res. 2017 Sep 12; 17(1):647. PMID: 28899394.
      View in: PubMed
    26. Rogers ES, Gillespie C, Smelson D, Sherman SE. A qualitative evaluation of mental health clinic staff perceptions of barriers and facilitators to treating tobacco use. Nicotine Tob Res. 2017 Sep 07. PMID: 29059344.
      View in: PubMed
    27. Trojano ML, Christopher PP, Pinals DA, Harnish A, Smelson D. Perceptions of voluntary consent among jail diverted veterans with co-occurring disorders. Behav Sci Law. 2017 Sep; 35(5-6):408-417. PMID: 28762534.
      View in: PubMed
    28. Blonigen DM, Rodriguez AL, Manfredi L, Nevedal A, Rosenthal J, McGuire JF, Smelson D, Timko C. Cognitive-Behavioral Treatments for Criminogenic Thinking: Barriers and Facilitators to Implementation Within the Veterans Health Administration. Psychol Serv. 2017 May 18. PMID: 28517949.
      View in: PubMed
    29. Simmons MM, Gabrielian S, Byrne T, McCullough MB, Smith JL, Taylor TJ, O'Toole TP, Kane V, Yakovchenko V, McInnes DK, Smelson DA. A Hybrid III stepped wedge cluster randomized trial testing an implementation strategy to facilitate the use of an evidence-based practice in VA Homeless Primary Care Treatment Programs. Implement Sci. 2017 Apr 04; 12(1):46. PMID: 28376839.
      View in: PubMed
    30. Chinman M, McCarthy S, Hannah G, Byrne TH, Smelson DA. Using Getting To Outcomes to facilitate the use of an evidence-based practice in VA homeless programs: a cluster-randomized trial of an implementation support strategy. Implement Sci. 2017 Mar 09; 12(1):34. PMID: 28279207.
      View in: PubMed
    31. Corrigan P, Schomerus G, Smelson D. Are some of the stigmas of addictions culturally sanctioned? Br J Psychiatry. 2017 Mar; 210(3):180-181. PMID: 28249945.
      View in: PubMed
    32. Corrigan PW, Schomerus G, Shuman V, Kraus D, Perlick D, Harnish A, Kulesza M, Kane-Willis K, Qin S, Smelson D. Developing a research agenda for reducing the stigma of addictions, part II: Lessons from the mental health stigma literature. Am J Addict. 2017 Jan; 26(1):67-74. PMID: 27875626.
      View in: PubMed
    33. Corrigan P, Schomerus G, Shuman V, Kraus D, Perlick D, Harnish A, Kulesza M, Kane-Willis K, Qin S, Smelson D. Developing a research agenda for understanding the stigma of addictions Part I: Lessons from the Mental Health Stigma Literature. Am J Addict. 2017 Jan; 26(1):59-66. PMID: 27779803.
      View in: PubMed
    34. Harnish A, Corrigan P, Byrne T, Pinals DA, Rodrigues S, Smelson D. Substance Use and Mental Health Stigma in Veterans With Co-Occurring Disorders. J Dual Diagn. 2016 Jul-Dec; 12(3-4):238-243. PMID: 27723432.
      View in: PubMed
    35. Ellison ML, Schutt RK, Glickman ME, Schultz MR, Chinman M, Jensen K, Mitchell-Miland C, Smelson D, Eisen S. Patterns and predictors of engagement in peer support among homeless veterans with mental health conditions and substance use histories. Psychiatr Rehabil J. 2016 Sep; 39(3):266-73. PMID: 27618463.
      View in: PubMed
    36. Krebs P, Rogers E, Smelson D, Fu S, Wang B, Sherman S. Relationship between tobacco cessation and mental health outcomes in a tobacco cessation trial. J Health Psychol. 2016 May 04. PMID: 27151069.
      View in: PubMed
    37. Smelson DA, Zaykowski H, Guevermont N, Siegfriedt J, Sawh L, Modzelewski D, Tsemberis S, Kane V. Integrating Permanent Supportive Housing and Co-Occurring Disorders Treatment for Individuals Who Are Homeless. J Dual Diagn. 2016 Apr-Jun; 12(2):193-201. PMID: 27064939.
      View in: PubMed
    38. Okunna NC, Rodriguez-Monguio R, Smelson DA, Poudel KC, Volberg R. Gambling involvement indicative of underlying behavioral and mental health disorders. Am J Addict. 2016 Mar; 25(2):160-72. PMID: 26871884.
      View in: PubMed
    39. Blonigen DM, Rodriguez AL, Manfredi L, Britt J, Nevedal A, Finlay AK, Rosenthal J, Smelson D, Timko C. The Availability and Utility of Services to Address Risk Factors for Recidivism among Justice-Involved Veterans. Crim Justice Policy Rev. 2017 10; 28(8):790-813. PMID: 26924887.
      View in: PubMed
    40. Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, Timko C, Frayne SM, Smelson D, Oliva E, Binswanger I. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016 Mar 01; 160:222-6. PMID: 26832998.
      View in: PubMed
    41. Finlay AK, Stimmel M, Blue-Howells J, Rosenthal J, McGuire J, Binswanger I, Smelson D, Harris AH, Frayne SM, Bowe T, Timko C. Use of Veterans Health Administration Mental Health and Substance Use Disorder Treatment After Exiting Prison: The Health Care for Reentry Veterans Program. Adm Policy Ment Health. 2015 Dec 21. PMID: 26687114.
      View in: PubMed
    42. Rogers ES, Smelson DA, Gillespie CC, Elbel B, Poole S, Hagedorn HJ, Kalman D, Krebs P, Fang Y, Wang B, Sherman SE. Telephone Smoking-Cessation Counseling for Smokers in Mental Health Clinics: A Patient-Randomized Controlled Trial. Am J Prev Med. 2016 Apr; 50(4):518-27. PMID: 26711163.
      View in: PubMed
    43. Carreiro S, Fang H, Zhang J, Wittbold K, Weng S, Mullins R, Smelson D, Boyer EW. iMStrong: Deployment of a Biosensor System to Detect Cocaine Use. J Med Syst. 2015 Dec; 39(12):186. PMID: 26490144.
      View in: PubMed
    44. Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. Drug Alcohol Depend. 2015 Nov 01; 156:243-53. PMID: 26454835.
      View in: PubMed
    45. McInnes DK, Fix GM, Solomon JL, Petrakis BA, Sawh L, Smelson DA. Preliminary needs assessment of mobile technology use for healthcare among homeless veterans. PeerJ. 2015; 3:e1096. PMID: 26246964.
      View in: PubMed
    46. Smelson DA, Chinman M, McCarthy S, Hannah G, Sawh L, Glickman M. A cluster randomized Hybrid Type III trial testing an implementation support strategy to facilitate the use of an evidence-based practice in VA homeless programs. Implement Sci. 2015 May 28; 10:79. PMID: 26018048.
      View in: PubMed
    47. DiGirolamo GJ, Smelson D, Guevremont N. Cue-induced craving in patients with cocaine use disorder predicts cognitive control deficits toward cocaine cues. Addict Behav. 2015 Aug; 47:86-90. PMID: 25900705.
      View in: PubMed
    48. Finlay AK, Binswanger IA, Smelson D, Sawh L, McGuire J, Rosenthal J, Blue-Howells J, Timko C, Blodgett JC, Harris AH, Asch SM, Frayne S. Sex differences in mental health and substance use disorders and treatment entry among justice-involved Veterans in the Veterans Health Administration. Med Care. 2015 Apr; 53(4 Suppl 1):S105-11. PMID: 25767963.
      View in: PubMed
    49. Carreiro S, Smelson D, Ranney M, Horvath KJ, Picard RW, Boudreaux ED, Hayes R, Boyer EW. Real-time mobile detection of drug use with wearable biosensors: a pilot study. J Med Toxicol. 2015 Mar; 11(1):73-9. PMID: 25330747.
      View in: PubMed
    50. McInnes DK, Sawh L, Petrakis BA, Rao S, Shimada SL, Eyrich-Garg KM, Gifford AL, Anaya HD, Smelson DA. The potential for health-related uses of mobile phones and internet with homeless veterans: results from a multisite survey. Telemed J E Health. 2014 Sep; 20(9):801-9. PMID: 25046280.
      View in: PubMed
    51. Finlay AK, Smelson D, Sawh L, McGuire J, Rosenthal J, Blue-Howells J, Timko C, Binswanger I, Frayne SM, Blodgett JC, Bowe T, Clark SC, Harris AHS. U.S. Department of Veterans Affairs Veterans Justice Outreach Program: Connecting Justice-Involved Veterans with Mental Health and Substance Use Disorder Treatment. Crim Justice Policy Rev. 2016; 27(2). PMID: 32180665.
      View in: PubMed
    52. Rogers E, Fernandez S, Gillespie C, Smelson D, Hagedorn HJ, Elbel B, Kalman D, Axtmayer A, Kurowski K, Sherman SE. Telephone care coordination for smokers in VA mental health clinics: protocol for a hybrid type-2 effectiveness-implementation trial. Addict Sci Clin Pract. 2013 Mar 15; 8:7. PMID: 23497630.
      View in: PubMed
    53. Smelson DA, Kline A, Kuhn J, Rodrigues S, O'Connor K, Fisher W, Sawh L, Kane V. A wraparound treatment engagement intervention for homeless veterans with co-occurring disorders. Psychol Serv. 2013 May; 10(2):161-7. PMID: 23244030.
      View in: PubMed
    54. Smelson D, Yu L, Buyske S, Gonzalez G, Tischfield J, Deutsch CK, Ziedonis D. Genetic association of GABA-A receptor alpha-2 and mu opioid receptor with cocaine cue-reactivity: evidence for inhibitory synaptic neurotransmission involvement in cocaine dependence. Am J Addict. 2012 Sep-Oct; 21(5):411-5. PMID: 22882391.
      View in: PubMed
    55. Smelson D, Chen KW, Ziedonis D, Andes K, Lennox A, Callahan L, Rodrigues S, Eisenberg D. A pilot study of Qigong for reducing cocaine craving early in recovery. J Altern Complement Med. 2013 Feb; 19(2):97-101. PMID: 22757968.
      View in: PubMed
    56. Boyer EW, Fletcher R, Fay RJ, Smelson D, Ziedonis D, Picard RW. Preliminary efforts directed toward the detection of craving of illicit substances: the iHeal project. J Med Toxicol. 2012 Mar; 8(1):5-9. PMID: 22311668.
      View in: PubMed
    57. Ellison ML, Mueller L, Smelson D, Corrigan PW, Torres Stone RA, Bokhour BG, Najavits LM, Vessella JM, Drebing C. Supporting the education goals of post-9/11 veterans with self-reported PTSD symptoms: a needs assessment. Psychiatr Rehabil J. 2012; 35(3):209-17. PMID: 22246119.
      View in: PubMed
    58. Smelson D, Kalman D, Losonczy MF, Kline A, Sambamoorthi U, Hill LS, Castles-Fonseca K, Ziedonis D. A brief treatment engagement intervention for individuals with co-occurring mental illness and substance use disorders: results of a randomized clinical trial. Community Ment Health J. 2012 Apr; 48(2):127-32. PMID: 20859765.
      View in: PubMed
    59. Boyer EW, Smelson D, Fletcher R, Ziedonis D, Picard RW. Wireless Technologies, Ubiquitous Computing and Mobile Health: Application to Drug Abuse Treatment and Compliance with HIV Therapies. J Med Toxicol. 2010 Jun; 6(2):212-6. PMID: 20623215.
      View in: PubMed
    60. Kalman D, Kim S, DiGirolamo G, Smelson D, Ziedonis D. Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs. Clin Psychol Rev. 2010 Feb; 30(1):12-24. PMID: 19748166.
      View in: PubMed
    61. Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2011 Jul; 37(4):727-36. PMID: 19933540.
      View in: PubMed
    62. Banerjea R, Pogach LM, Smelson D, Sambamoorthi U. Mental illness and substance use disorders among women veterans with diabetes. Womens Health Issues. 2009 Nov-Dec; 19(6):446-56. PMID: 19879456.
      View in: PubMed
    63. Fortuna JL, Smelson DA. The phenomenon of drug craving. J Psychoactive Drugs. 2008 Sep; 40(3):255-61. PMID: 19004417.
      View in: PubMed
    64. Banerjea R, Sambamoorthi U, Smelson D, Pogach LM. Expenditures in mental illness and substance use disorders among veteran clinic users with diabetes. J Behav Health Serv Res. 2008 Jul; 35(3):290-303. PMID: 18512155.
      View in: PubMed
    65. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16. PMID: 18840032.
      View in: PubMed
    66. Banerjea R, Sambamoorthi U, Smelson D, Pogach LM. Chronic illness with complexities: mental illness and substance use among Veteran clinic users with diabetes. Am J Drug Alcohol Abuse. 2007; 33(6):807-21. PMID: 17994477.
      View in: PubMed
    67. Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol. 2006 Dec; 26(6):666-7. PMID: 17110828.
      View in: PubMed
    68. Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006 Feb; 26(1):9-12. PMID: 16415698.
      View in: PubMed
    69. Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend. 2006 Jul 27; 83(3):233-7. PMID: 16384655.
      View in: PubMed
    70. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. PMID: 16184072.
      View in: PubMed
    71. Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, Kaune M. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004 Jul; 27(1):45-9. PMID: 15223093.
      View in: PubMed
    72. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003 Nov 26; 290(20):2693-702. PMID: 14645311.
      View in: PubMed
    73. Ziedonis D, Williams JM, Smelson D. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci. 2003 Oct; 326(4):223-30. PMID: 14557739.
      View in: PubMed
    74. Smelson DA, Davis CW, Eisenstein N, Engelhart C, Williams J, Losonczy MF, Ziedonis D. Cognitive disparity in schizophrenics with and without cocaine dependency. J Subst Abuse Treat. 2003 Jan; 24(1):75-9. PMID: 12646333.
      View in: PubMed
    75. Smelson DA, Losonczy MF, Kilker C, Starosta A, Kind J, Williams J, Ziedonis D. An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine. Psychiatr Serv. 2002 Dec; 53(12):1612-6. PMID: 12461224.
      View in: PubMed
    76. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002 Sep; 47(7):671-5. PMID: 12355680.
      View in: PubMed
    77. Smelson DA, Davis CW, Di Pano R, Johnson V, Losonczy MF, Ziedonis D. Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug-abusing schizophrenics. J Nerv Ment Dis. 2002 Mar; 190(3):200-2. PMID: 11923656.
      View in: PubMed
    78. Carol G, Smelson DA, Losonczy MF, Ziedonis D. Alcohol & drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiatr Serv. 2001 Aug; 52(8):1029-31. PMID: 11474045.
      View in: PubMed
    79. Smelson DA, Roy A, Roy M, Tershakovec D, Engelhart C, Losonczy MF. Electroretinogram and cue-elicited craving in withdrawn cocaine-dependent patients: a replication. Am J Drug Alcohol Abuse. 2001 May; 27(2):391-7. PMID: 11417946.
      View in: PubMed
    80. Smelson DA, Roy A, Santana S, Engelhart C. Neuropsychological deficits in withdrawn cocaine-dependent males. Am J Drug Alcohol Abuse. 1999 May; 25(2):377-81. PMID: 10395167.
      View in: PubMed
    81. Smelson DA, McGee-Caulfield E, Bergstein P, Engelhart C. Initial validation of the Voris Cocaine Craving Scale: a preliminary report. J Clin Psychol. 1999 Jan; 55(1):135-9. PMID: 10100840.
      View in: PubMed
    82. Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Stern RG, Losonczy MF. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999 Jan; 60(1):41-4. PMID: 10074877.
      View in: PubMed
    83. Smelson DA, Roy M, Roy A, Santana S. Electroretinogram in withdrawn cocaine-dependent subjects. Relationship to cue-elicited craving. Br J Psychiatry. 1998 Jun; 172:537-9. PMID: 9828997.
      View in: PubMed
    84. Roy A, Roy M, Smelson DA. Risperidone, ERG and cocaine craving. Am J Addict. 1998; 7(1):90. PMID: 9522012.
      View in: PubMed
    85. Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997 Nov; 42(9):984. PMID: 9429074.
      View in: PubMed
    86. Roy M, Roy A, Smelson D, Brown S, Weinberger L. Reduced blue cone electroretinogram in withdrawn cocaine dependent patients: a replication. Biol Psychiatry. 1997 Oct 1; 42(7):631-3. PMID: 9376460.
      View in: PubMed
    87. Smelson DA, Kordon ME, Rudolph B. Evaluating the diagnostic interview: obstacles and future directions. J Clin Psychol. 1997 Aug; 53(5):497-505. PMID: 9257229.
      View in: PubMed
    88. Desai P, Roy M, Roy A, Brown S, Smelson D. Impaired color vision in cocaine-withdrawn patients. Arch Gen Psychiatry. 1997 Aug; 54(8):696-9. PMID: 9283503.
      View in: PubMed
    89. Smelson DA, Roy A, Roy M. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry. 1997 May; 42(4):431. PMID: 9161774.
      View in: PubMed
    90. Roy M, Roy A, Williams J, Weinberger L, Smelson D. Reduced blue cone electroretinogram in cocaine-withdrawn patients. Arch Gen Psychiatry. 1997 Feb; 54(2):153-6. PMID: 9040283.
      View in: PubMed
    91. Roy M, Smelson D, Roy A. Longitudinal study of blue cone retinal function in cocaine-withdrawn patients. Biol Psychiatry. 1997 Jan 15; 41(2):252-3. PMID: 9018402.
      View in: PubMed
    92. Roy A, Smelson D, Lindeken S. Screening for pathological gambling among substance misusers. Br J Psychiatry. 1996 Oct; 169(4):523. PMID: 8894208.
      View in: PubMed
    93. Smelson DA, Roy A, Roy M. The electroretinogram and neuropsychological functioning in cocaine addicts. Can J Psychiatry. 1996 Aug; 41(6):415. PMID: 8862864.
      View in: PubMed
    94. Roy M, Smelson DA, Roy A. Abnormal electroretinogram in cocaine-dependent patients. Relationship to craving. Br J Psychiatry. 1996 Apr; 168(4):507-11. PMID: 8730949.
      View in: PubMed
    95. Smelson DA. Adolescent substance abuse prevention. N J Med. 1993 Nov; 90(11):845-8. PMID: 8272276.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Smelson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _